Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype

AIDS

Volumn 15, Issue 5, 2001, Pages 553-561

  Van Laethem, Kristel ^a,b,c   Witvrouw, Myriam ^a,b,c   Pannecouque, Christophe ^a,b,c   Van Remoortel, Barbara ^a,b,c   Schmit, Jean Claude ^a,b,c   Esnouf, Robert ^a,b,c   Kleim, Jörg Peter ^a,b,c   Balzarini, Jan ^a,b,c   Desmyter, Jan ^a,b,c   De Clercq, Erik ^a,b,c   Vandamme, Anne Mieke ^a,b,c,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^c GLAXOSMITHKLINE   (United Kingdom)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiretroviral therapy; HIV resistance mutations; Multi nucleoside resistance; Phenotypic reversal; Reverse transcriptase inhibitors

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ABACAVIR; ADEFOVIR; ALPHA INTERFERON; DELAVIRDINE; DIDANOSINE; EMIVIRINE; FOSCARNET; LAMIVUDINE; LOVIRIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TALVIRALINE; TENOFOVIR; TIVIRAPINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; VIRUS MUTANT;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; BINDING SITES; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MUTATION; NUCLEOSIDES; PHENOTYPE; QUINOXALINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035970694     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200103300-00003     Document Type: Article

References (42)

1. Anti-human immunodeficiency virus drug combination strategies
2. Managing resistance to anti-HIV drugs
3. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations
4. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: An in vitro comparative study
5. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
6. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain
7. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries
8. Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir
9. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
10. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs
11. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance
12. A short-term clinical evaluation of L-697,661, a non- nucleoside inhibitor of HIV-1 reverse transcriptase
13. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
14. Characterization of HIV-1 strains isolated from patients treated with TIBO R82913
15. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy
16. Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains
17. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus
18. Targeting delavirdine/atevirdine resistant HIV-1: Identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors
19. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transciptase inhibitor-resistant human immunodeficiency virus isolates
20. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720
21. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase
22. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication
23. In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097
24. Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine
25. HIV with reduced sensitivity to zidovudine (ZDV) isolated during prolonged therapy
26. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine
27. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs
28. Fidelity analysis of HIV-1 reverse transcriptase mutants with an altered amino acid sequence at residues Leu74, Glu89, Tyr115, Tyr183 and Met184
29. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
30. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: Inhibitor flexibility is a useful design feature for reducing drug resistance
31. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74 → Val or Ile and Val-75 → Leu or Ile) HIV-1 mutants
32. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer
33. A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781
34. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance
35. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
36. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial
37. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
38. Resistance profile and cross-resistance of HIV-1 among 102 patients failing nonnucleoside reverse transcriptase inhibitor-containing regimen
39. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and 1-2′,3′-dideoxy-3′-thiacytidine
40. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
41. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: A meta-analysis of controlled trials
42. Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study